Rebeca Romero Aburto PhD is an Imagion Biosystems research collaborator and a post-doctoral fellow at the University of Texas MD Anderson Cancer Center. As an invited speaker at November 2016’s meeting of the NCI Alliance for Nanotechnology in Bethesda, MD, Dr. Romero presented her work on advanced magnetic nanoparticle surface modifications. Data presented show a new micellar iron oxide nanoparticle that can accommodate a variety of cancer-targeting antibodies, is stable in biological media including human plasma, and persists in mammalian circulation for two hours — long enough for nanoparticles to encounter and attach to cancer cells, if present, for specific, sensitive tumor detection.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer